Cephalosporin Prescribing Falls Short of Guidelines in Tertiary Care

Cephalosporins are a global mainstay in hospitals, known for broad-spectrum coverage and a familiar safety profile. But that familiarity fosters habits that outpace the evidence. In South India, a prospective study at one tertiary center scrutinized cephalosporin prescribing against guidelines, tracking appropriateness, local resistance, drug interactions, and de-escalation once cultures were back.¹ The deep dive revealed widespread gaps. Separately, researchers in South Africa ran three point prevalence surveys at a referral center, characterizing broader antimicrobial prescribing and documenting guideline adherence.² The view was consistent.

Resistance complicates empirical prescribing, especially when resistance profiling is slow or missing.³ Both studies highlight a real-world dilemma: prescribers must weigh urgency against driving resistance with poor drug choices or extended broad-spectrum use. Third-generation cephalosporins, particularly, create strong selective pressure, fueling multidrug-resistant bugs. This is a problem.

South India’s prospective evaluation drilled down on cephalosporin prescribing in adult inpatients, measuring guideline adherence at every step, from initial choice to de-escalation.¹ This was a deep dive. It matched susceptibility and resistance profiles with prescribing choices, directly comparing empirical agents to actual sensitivity.¹ Drug-drug interactions with cephalosporins were also cataloged.¹ The study focused on adult patients across medical and surgical wards, representing common hospital-acquired and community-acquired infections. That provided a typical patient picture.

Across South Africa, point prevalence surveys painted a complementary picture of systemic prescribing. Three survey rounds at one tertiary referral hospital captured cross-sectional snapshots of every antimicrobial prescription on survey days.² The data included documented indication, guideline compliance, and stop or review dates. Repeating the survey rounds boosted reliability beyond a single audit.² All inpatient wards, including ICUs and specialty units, were covered. This offered a complete view.

Both investigations found cephalosporin and broader antimicrobial prescribing fell short of guideline standards in a clinically significant number of cases.^1,2 De-escalation was a particular weakness. South India’s resistance profiling confirmed empirical choices often clashed with susceptibility results in some prescriptions, exposing the cost of broad cover without a review plan.¹ This is a common pitfall. The South African surveys identified documentation gaps — missing indications and absent stop dates — across all rounds.² These look like structural failures, not just individual errors. Translating guidelines into consistent practice remains a persistent challenge in busy tertiary care. Time and uncertainty play a role.

The designs hold obvious caveats. Point prevalence surveys offer only a snapshot, unable to track outcomes or downstream effects.² The South India study, from a single tertiary center, may not reflect primary care or lower-resource settings.¹ Neither publication provided patient-level outcomes — mortality, length of stay, or Clostridioides difficile infection rates — meaning prescribing gaps aren't directly linked to patient harm. The South India work also focused solely on cephalosporins, possibly missing problems with other antibiotic classes. South African surveys relied on documented information, which might not capture full clinical rationale. The data show a problem. The next question is: what actually happens to patients?